| Course | NR 607 Diagnosis & Management in Psychiatric-Mental Health III Practicum |
|---|---|
| Week | 8 |
| Paper type | Synthesis case paper |
| Length | About 1,100 words, 4 pages |
| Format | APA 7 student paper |
| School | Chamberlain University |
| Program | MSN, Psychiatric-Mental Health Nurse Practitioner (PMHNP) |
| Updated | October 2026 |
Free sample paper for NR 607 Week 8
Synthesis Case Paper: K.A.'s Illness Was Managed for Five Years as a Series of Medication Problems, When the Pattern Across the Record Was Disruption and Undocumented Reasons
Student Name
College of Nursing, Chamberlain University
NR 607: Diagnosis & Management in Psychiatric-Mental Health III Practicum
Instructor Name
Month Day, Year
Synthesis Case Paper: K.A.'s Illness Was Managed for Five Years as a Series of Medication Problems, When the Pattern Across the Record Was Disruption and Undocumented Reasons
The Claim
For five years, K.A.'s schizophrenia was treated as a sequence of medication problems: one antipsychotic after another, each judged on whether the voices went away. Looking at the whole record, the stronger pattern was different. Every relapse followed a disruption, a lost phone, a changed bus route, a lease ending, and every repeated mistake followed a reason that was never written down. The turn came when someone finally treated both as part of the illness.
Evidence From the Whole Period
Relapse 1, 2020: followed stopping risperidone because of sexual side effects that K.A. had not mentioned to the prescriber. The reason was recorded only later.
Relapse 2, 2022: followed six months of olanzapine at about 60% of doses. The pharmacy data existed; nobody looked at them until after the overdose.
Missed injections, 2023 to 2025: five in three years. Two coincided with a bus route change, one with a lost phone, two before the third admission, when K.A. had moved rooms.
Repeated mistake, 2024: olanzapine restarted at urgent care because the discharge summary did not say why it had stopped.
The turn, late 2026: the outpatient team treated housing as a clinical problem, writing a coordination note that secured a placement; checked every trial for adequacy before calling the illness resistant; and asked hematology a precise question that let clozapine start safely.
The Strongest Reading Against
A reasonable colleague would say: this was always a medication problem. K.A. has treatment-resistant schizophrenia, and what changed in 2026 was clozapine, the one drug known to work in resistant illness (Kane et al., 1988). Housing and documentation are important, but the voices quieted because of the drug.
This reading has real force. Clozapine did reduce the voices more than any previous medicine. But it does not explain why clozapine took six years to reach. Under the consensus criteria, K.A. could have been identified as treatment-resistant in 2023, after risperidone and aripiprazole (Howes et al., 2017). Clozapine was delayed by the very things the claim names: uncertainty about adherence that pharmacy data could have settled, missed injections tied to disruption and no one asking the low neutrophil question until 2026. The medication answer was available earlier; the system around it was not ready to deliver it.
What Did Not Improve
Cannabis: reduced to every other night, not stopped. K.A. may still be harming recovery.
Tobacco: down from 10 to 4 cigarettes a day with patches; smoking changes affect clozapine levels and need watching.
Weight: unchanged on clozapine so far; metformin continued.
Friendships: K.A. still has no social contact outside work and family.
Negative symptoms: low motivation persists, and clozapine has less effect on it.
The Neutrophil Question as an Example
The low neutrophil count was in K.A.'s record from 2020. Each time clozapine was mentioned, it was set aside with a note about "low counts." Nobody asked whether the counts were normal for K.A. When the question was finally asked, a Duffy phenotype test answered it in a week, and a systematic review supported starting clozapine under adjusted thresholds (Manu et al., 2016). This was another undocumented reason, "low counts," doing the work of a decision that had never been made.
What the Turn Required
It required three people to act on parts of the record that had been treated as background. The outpatient team counted the injection gaps instead of the injections. The housing case manager received a request with a date. The hematologist received a question precise enough to answer at the first visit. None of these was a new treatment; each was a way of making the existing treatment reach K.A.
Why the Claim Matters
If K.A.'s story were simply a story about a drug, the lesson would be to reach clozapine sooner. That is part of it. But the drug could not have been delivered in 2023 any more than in 2026 without someone dealing with housing, transport, missed injections and the neutrophil question. The lesson for practice is broader: treatment resistance in a person with unstable circumstances must be judged on trials that were actually delivered, and the barriers to delivery are part of the clinical picture.
Twelve Weeks On
At twelve weeks on clozapine 350 mg daily, K.A. said the voices were now mostly silent during the day, kept the grocery job and moved into a studio with tenancy support. The sister still delivers the weekly packs. K.A. has had no missed blood tests, helped by the team nurse who visits on the day of each test.
What This Means for Practice
Three things would have changed K.A.'s course earlier: recording the reason each medicine stopped; checking pharmacy fills before deciding a trial failed; and treating housing and transport as clinical facts, recorded and acted on like symptoms.
The Handover Test
If K.A. moved to a new team tomorrow, would the record let them avoid the old mistakes? The longitudinal summary now lists each trial with dose, duration and reason for ending. The transition summary gives the exact current regimen and assigns each unfinished task to a named owner. The safety plan is in K.A.'s words. The hematology reply is filed with the adjusted thresholds. A new prescriber would not restart olanzapine, would not stop clozapine for a count of 1,200 and would know to call K.A.'s sister first. The record passes the test now; it did not in 2024.
What a Colleague Taking Over Should Know First
In order of importance, with each item traceable to a section of the record, so the colleague can check it rather than take it on trust, and so that the handover itself becomes evidence of whether the record works:
That the voices responded to clozapine after four failed or inadequate trials; that the neutrophil count is normally low for K.A. and the adjusted thresholds apply; that relapses have followed disruption and missed medicine; that the sister is the first contact; and that cannabis and tobacco are both still in use and both affect clozapine.
Limits
The claim is drawn from one person's record. Some of the earlier records were incomplete, which is part of the point, but also means some links are inferred.
References
Howes, O. D., McCutcheon, R., Agid, O., de Bartolomeis, A., van Beveren, N. J. M., Birnbaum, M. L., Bloomfield, M. A. P., Bressan, R. A., Buchanan, R. W., Carpenter, W. T., Castle, D. J., Citrome, L., Daskalakis, Z. J., Davidson, M., Drake, R. J., Dursun, S., Ebdrup, B. H., Elkis, H., Falkai, P., ... Correll, C. U. (2017). Treatment-resistant schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. American Journal of Psychiatry, 174(3), 216-229. https://doi.org/10.1176/appi.ajp.2016.16050503
Kane, J., Honigfeld, G., Singer, J., & Meltzer, H. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45(9), 789-796. https://doi.org/10.1001/archpsyc.1988.01800330013001
Manu, P., Sarvaiya, N., Rogozea, L. M., Kane, J. M., & Correll, C. U. (2016). Benign ethnic neutropenia and clozapine use: A systematic review of the evidence and treatment recommendations. The Journal of Clinical Psychiatry, 77(7), e909-e916. https://doi.org/10.4088/JCP.15r10085
The Chamberlain NR 607 Week 8 instructions
The Week 8 paper makes a claim and defends it, for example that an illness was managed as a series of medication problems when the pattern was a housing one. Draw evidence from the whole period, not the last month. Give the reading a reasonable colleague would hold against yours, at its strongest, and answer it. Report what did not improve. Apply a handover test: would the record let a new team avoid the old mistakes? Most rubrics mark down a chronicle with no claim, a paper reporting only what went well, no alternative reading and a conclusion praising the writer's own growth. Report what did not improve.
How the NR 607 Week 8 example is put together
The sample states its claim, then supports it with each relapse, the missed injections and the restarted olanzapine, each linked to disruption or a missing reason. The turn in 2026 is described as treating housing, adherence counting and the neutrophil question as clinical. The opposing reading, that clozapine did the work, is set out and answered by showing why clozapine came late. The neutrophil question is used as a further example. What did not improve is listed: cannabis, tobacco, weight, friendships and negative symptoms. Sections cover what the turn required, the twelve-week result, why the claim matters, practice implications, a handover test, what a colleague should know first and limits.
Reading the NR 607 Week 8 grading rubric
The heaviest loss is the chronicle, everything in order with no claim; this paper's claim is stated first and defended. Reporting only what went well costs the next share, while five areas that did not improve are listed. No alternative reading loses a row, and the clozapine argument is given its full force before being answered. A conclusion praising the writer's own growth loses marks, and this paper never mentions the writer's growth. The handover test earns the final criterion by checking the record against a new team's needs. Describing what the turn required, three people acting on overlooked parts of the record, makes the claim concrete. Listing what a colleague should know first applies the handover test in practice.
NR 607 Week 8 help: mistakes that cost points
Weak NR 607 Week 8 papers retell the case from start to finish. Others report only successes. Many never consider how a colleague might read the same history differently. Conclusions often describe what the writer learned. Few test whether the record would serve the next team. State a claim someone could dispute, support it with evidence from across the whole period, give the strongest opposing view and answer it, list what did not improve and test the record against a handover. If your case differs, share its course, and a synthesis built around a claim can be drafted. Answer the opposing reading with evidence, not dismissal.
Get a NR 607 Week 8 example written to your instructions
Send the Week 8 prompt from your classroom, the rubric if you have it, and the case you have been carrying, and a custom example is written to all three and returned inside 24 to 48 hours. The first one is free. Tell us the claim you want argued and it will be argued.
More NR 607 papers and PMHNP samples
- NR 607 Week 1: Missing Fact in the Record Post
- NR 607 Week 2: Longitudinal Case Write-Up
- NR 607 Week 3: Safety Plan Write-Up
- NR 607 Week 4: Care Coordination Note
- NR 607 Week 5: Treatment Resistance Case Analysis
- NR 607 Week 6: Transition of Care Summary
- NR 607 Week 7: Hematology Consultation Write-Up
- NR 606 Week 8: Complex Case Paper
- NR 546 Week 8: Psychopharmacology Case Paper
- NR 605 Week 8: Management Case Paper
- NR 547 Week 8: Diagnostic Case Paper
NR 607 Week 8 questions, answered
How long is a synthesis paper?
Longer than the weekly work and usually bounded by a page or word range your section publishes. Length matters less than whether one claim runs the whole way through. Papers padded with background about the condition are marked down against ones spending that same space defending an argument, since general material is not what the week is testing.
Can I reuse my earlier assignments?
Check what your section permits before reusing anything, since policies on building on your own submitted work differ. Where it is allowed, the material still has to be rewritten toward the claim rather than pasted in. Sections stitched together out of earlier weeks read as seams, and a marker sees the change of purpose immediately.
What makes a conclusion strong here?
Naming what is still unresolved and what the next clinician has to watch. Conclusions that summarize the paper again add nothing, and ones describing personal growth belong in a reflection rather than a case paper. The strongest close leaves a reader with the open questions and a clear sense of who is responsible for each.
Where can I find a free NR 607 Week 8 sample paper?
The full synthesis case paper arguing that disruption, not medication alone, shaped five years of schizophrenia is published on this page.
What is the opposing reading in the NR 607 Week 8 paper?
That clozapine, the one drug known to work in resistant illness, made the difference; the paper answers that the barriers delayed clozapine for years.